NEW YORK, May 11, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, Inc. ("Puma Biotechnology") (NASDAQ:PBYI) between February 29, 2016 and May 4, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Central District of California. To get more information go to:
http://www.zlk.com/pslra-sb/puma-biotechnology-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company did not anticipate that the U.S. Food and Drug Administration (“FDA”) would ultimately approve PB272 (“neratinib”) for the treatment of breast cancer; (ii) as such, Puma Biotechnology had overstated the drug’s approval prospects and/or commercial viability; and (iii) as a result, Puma Biotechnology’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Puma Biotechnology you have until July 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 



